AEBP1 Promotes Epithelial-Mesenchymal Transition of Gastric Cancer Cells by Activating the NF-κB Pathway and Predicts Poor Outcome of the Patients

Jun-yan Liu,Lei Jiang,Jia-jia Liu,Tao He,You-hong Cui,Feng Qian,Pei-wu Yu
DOI: https://doi.org/10.1038/s41598-018-29878-6
IF: 4.6
2018-01-01
Scientific Reports
Abstract:Adipocyte enhancer binding protein 1 (AEBP1) is a transcriptional repressor that plays a critical role in regulating adipogenesis. Recent studies have indicated that AEBP1 might function as a candidate oncogene and is overexpressed in several human malignancies. However, the role of AEBP1 in gastric cancer (GC) remains largely unknown. This study aimed to investigate the expression pattern, prognostic significance and biological function of AEBP1 in human gastric cancer and to explore the underlying mechanism. We found that both the mRNA and protein levels of AEBP1 were significantly increased in human GC tissues. Elevated AEBP1 expression was significantly correlated with poor overall survival in patients with both early-stage (Tumor, Node, Metastases (TNM) TNM I and II) and late-stage (TNM III and IV) GC. Silencing AEBP1 markedly suppressed the proliferation, migration, invasion, metastasis and epithelial-mesenchymal transition of GC cells. Moreover, we demonstrated that knockdown of AEBP1 in GC cells led to inhibition of the NF-κB pathway by hampering the degradation of IκBα. Thus, AEBP1 might be served as a promising prognostic indicator and a potential therapeutic target in human GC.
What problem does this paper attempt to address?